Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-tumor drug-resistant mesoporous titania nano pharmaceutical composition and preparation method thereof

A technology of mesoporous titanium dioxide and nano-drugs, which is applied in the direction of nano-drugs, anti-tumor drugs, drug combinations, etc., can solve the problems of weak penetration ability and application limitations, and achieve the goals of reasonable method design, simple preparation process, and improved killing effect Effect

Active Publication Date: 2018-10-09
DALIAN UNIV OF TECH
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the weak penetrating ability of ultraviolet light, its application as a drug delivery carrier is limited.
In summary, there is currently no composition that combines many materials to overcome tumor drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor drug-resistant mesoporous titania nano pharmaceutical composition and preparation method thereof
  • Anti-tumor drug-resistant mesoporous titania nano pharmaceutical composition and preparation method thereof
  • Anti-tumor drug-resistant mesoporous titania nano pharmaceutical composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The first step is to synthesize the targeting material—cyclic pentapeptide-hyaluronic acid (ADH-1-HA)

[0038] Precisely weigh 31mg of sodium hyaluronate, dissolve it in deionized water and place it in an eggplant-shaped bottle, hydrate for 24 hours, then add 23.4mg of EDC and 14.1mg of NHS dropwise to the aqueous solution of sodium hyaluronate to adjust the pH to 6.5, After activating for 2 hours, 5 mg of cyclopentapeptide ADH-1 was added to the above solution, and reacted for 48 hours at room temperature under stirring conditions. After the reaction, the reaction solution was transferred to a dialysis bag with a molecular weight cut-off of 3500, clamped at both ends, and dialyzed with deionized water for 48 hours for purification; after the solution in the dialysis bag was freeze-dried, the product ADH-1-HA was obtained .

[0039] The obtained samples were characterized by H NMR spectroscopy. figure 2 It is the proton nuclear magnetic resonance spectrum of ADH-1-HA...

Embodiment 2

[0065] Change the mass of 5 mg and 31 mg of ADH-1 peptide and HA in the first step to 9.1 mg and 31 mg; change the 100 μl of n-heptanoic acid in the second step to 50 μl, change the 300 μl of tetrabutyl titanate to 400 μl, and change the reaction time to 15 minutes. The hydrothermal reaction time was changed from 120°C to 110°C for 20min, and the hydrothermal time was changed from 40min to 45min, and the APTMS was changed from 100μl to 200μl; the quality of ADH-1-HA and amino-modified mesoporous titanium dioxide in the third step was changed from 5mg and 10mg 5 mg and 5 mg; other preparation conditions remain unchanged, and an anti-tumor drug-resistant mesoporous titanium dioxide nano-medicine composition is prepared.

Embodiment 3

[0067] Change the mass of 5 mg and 31 mg of ADH-1 peptide and HA in the first step to 9.1 mg and 31 mg; change the 300 μl of tetrabutyl titanate in the second step to 350 μl, change the reaction time from 15 minutes to 20 minutes, and change the hydrothermal reaction from 120 ℃ was changed to 130 ℃, the hydrothermal time was changed from 40min to 50min, and the APTMS was changed from 100μl to 150μl; the mass of ADH-1-HA and amino-modified mesoporous titanium dioxide in the third step was changed from 5mg and 10mg to 5mg and 5mg; other preparation conditions Unchanged, anti-tumor drug-resistant mesoporous titania nano-drug compositions were prepared.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-tumor drug-resistant mesoporous titania nano pharmaceutical composition and a preparation method thereof and belongs to the field of pharmaceutical preparations. According to the mesoporous titania nano pharmaceutical composition, aminated mesoporous titania serves as a carrier, cyclic pentapeptide-hyaluronic acid ADH-1-HA serves as a targeting material, and adriamycin serves as a model drug. The preparation method comprises the following steps: taking sodium hyaluronate, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride EDC, N-hydroxy succinimide NHS and cyclic pentapeptide-ADH-1 as raw materials, and synthesizing an anti-tumor drug-resistant targeting material cyclic pentapeptide-hyaluronic acid ADH-1-HA; synthesizing amino-modified mesoporous titania nano particles; finally, adding the EDC and the NHS into the ADH-1-HA solution, adding the mesoporous titania nano particles, and reacting, thereby obtaining the product. The method disclosed bythe invention is reasonable in design and simple in preparation process, is capable of improving an effect of killing drug-resistant tumors, and has wide application prospects.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and provides an anti-tumor drug-resistant mesoporous titanium dioxide nano drug composition and a preparation method thereof, in particular to a novel anti-tumor drug-resistant mesoporous titanium dioxide drug-loaded nano drug composition actively targeting tumor EMT cells Granules and methods for their preparation. technical background [0002] Tumor cell drug resistance is the main factor leading to the failure of conventional tumor chemotherapy, and it is also an indicator of poor prognosis of patients. Therefore, how to overcome tumor drug resistance is crucial to improving the survival rate of cancer patients. The research on the relationship between epithelial-mesenchymal transition (EMT) and chemosensitivity and drug resistance is a frontier topic in the field of cancer chemotherapy, and it is also one of the recent research hotspots. Studies have confirmed that some cancer cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/69A61K31/704A61K41/00A61K47/54A61K47/61A61P35/00B82Y5/00
CPCA61K31/704A61K41/0057A61K47/54A61K47/61A61K47/6949A61P35/00B82Y5/00A61K2300/00
Inventor 郭兆明郑坤刘晔李文青崔昌浩马昆王黎
Owner DALIAN UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com